Federico Bolognani, M.D., Ph.D.

Vice President and Head, Clinical Science, Axial Therapeutics

SFARI Scientific Review Board, SPARK Scientific Advisory Board

Federico Bolognani obtained his M.D. and Ph.D. degrees from the National University of La Plata, Argentina. He has worked as a research fellow at the University of Manchester School of Medicine Molecular Medicine Unit, a research assistant professor at the University of New Mexico School of Medicine and a research associate at the Houston Methodist Hospital Department of Neurosurgery in the Texas Medical Center developing translational programs in neuroscience. In 2009, he moved to Basel, Switzerland, to lead the Novartis Safety Genomic group at the Novartis Institutes of Biomedical Research (NIBR) where he led a global group of medical doctors and researchers involved in translational drug development with a focus in safety. In 2013, he joined the Roche Neuroscience Disease Area, where he led different clinical programs to develop new drugs for neurodevelopmental conditions, especially autism spectrum disorder. Since 2018, he has worked in the biotechnology sector developing drugs for neuroscience indications, including autism (Therachon, VectivBio, Axial Therapeutics). Bolognani has published more than 50 neuroscience papers in journals such as Nature Medicine, Science Translational Medicine, Journal of Neuroscience, Autism, Autism Research, Molecular Psychiatry, Biological Psychiatry, amongst others.

Read More
Subscribe to our newsletter and receive SFARI funding announcements and news